[99mTc]Tc-MY6349探针用于Trop2靶向SPECT显像:从临床前到初步临床研究
研究开发了Trop2特异性分子探针[99mTc]Tc-MY6349,经临床前实验验证其结合亲和力与特异性后,在8例乳腺癌患者中开展初步临床研究,SPECT/CT可在注射后15分钟检出Trop2阳性肿瘤,并显示原发灶与转移灶的Trop2表达异质性,结果与[18F]FDG PET/CT进行比较。
要点
- [99mTc]Tc-MY6349经纯化后放射化学纯度大于95%,临床前实验显示其与Trop2受体结合具有特异性。
- 初步临床研究中,[99mTc]Tc-MY6349 SPECT/CT在注射示踪剂后15分钟成功检出Trop2阳性肿瘤。
- 延迟显像显示正常器官摄取降低而肿瘤滞留持续,并可显示Trop2表达异质性及原发与转移病灶。
核心结论
- [99mTc]Tc-MY6349成功制备,具有高结合亲和力和Trop2特异性;初步临床研究验证了[99mTc]Tc-MY6349 SPECT/CT在乳腺癌患者体内检测Trop2表达的安全性和可行性。
- 该显像方式可补充现有方法,有助于指导Trop2靶向治疗和推进个体化治疗,同时促进SPECT/CT核医学显像技术的应用。
研究设计与样本
- 临床前研究:通过免疫荧光和流式细胞术评估不同乳腺癌细胞系的Trop2表达,将Trop2特异性纳米抗体MY6349经C端GGGC标签进行99mTc定点标记,体外测试其与Trop2受体的结合亲和力,并通过SPECT显像和生物分布研究检查[99mTc]Tc-MY6349的体内肿瘤摄取与分布。
- 初步临床研究:在8例乳腺癌患者中开展[99mTc]Tc-MY6349 SPECT/CT显像,并与[18F]FDG PET/CT结果进行比较。
主要发现
- [99mTc]Tc-MY6349经纯化后放射化学纯度大于95%。
- 体外和体内实验证明[99mTc]Tc-MY6349与Trop2受体结合具有特异性。
- 体内显像和生物分布研究显示肿瘤摄取与Trop2表达水平之间呈显著相关。
- 初步临床研究中,[99mTc]Tc-MY6349 SPECT显像在注射示踪剂后15分钟成功检出Trop2阳性肿瘤。
- 延迟显像显示正常器官摄取降低,但[99mTc]Tc-MY6349在肿瘤中持续滞留;[99mTc]Tc-MY6349 SPECT/CT显像突出显示了Trop2表达异质性,并以良好的肿瘤-背景比显示乳腺癌原发和转移病灶。
临床怎么用
- 作者认为,该显像方式可补充现有方法,有助于指导Trop2靶向治疗和推进个体化治疗,同时促进SPECT/CT核医学显像技术的应用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The trophoblast cell-surface antigen 2 (Trop2) is markedly overexpressed in breast cancers, with a particularly high incidence in triple-negative breast cancer. The therapeutic relevance of Trop2 expression is underscored by the approval of an antibody-drug conjugate for triple-negative breast cancer treatment. However, there is no a predictive technique for accurate whole-body mapping of Trop2 expression in patients. In this study, we developed a novel Trop2-specific molecular probe, [99mTc]Tc-MY6349, and evaluated its safety and feasibility for detecting Trop2 expression in breast cancer using SPECT/CT imaging. Methods: Trop2 expression in different breast cancer cell lines was assessed via immunofluorescence and flow cytometry. The Trop2-specific nanobody MY6349 was site-specifically labeled with 99mTc via a C-terminal GGGC tag, and its binding affinity to the Trop2 receptor was tested in vitro. The in vivo tumor uptake and distribution of [99mTc]Tc-MY6349 were examined through SPECT imaging and biodistribution studies. Furthermore, a pilot clinical study of [99mTc]Tc-MY6349 SPECT/CT was conducted in 8 patients with breast cancer, and the results were compared with [18F]FDG PET/CT. Results: [99mTc]Tc-MY6349 achieved a greater than 95% radiochemical purity after purification. In vitro and in vivo experiments demonstrated the binding specificity of [99mTc]Tc-MY6349 to the Trop2 receptor. In vivo imaging and biodistribution studies revealed a significant correlation between tumor uptake and Trop2 expression levels. In the pilot clinical study, SPECT imaging with [99mTc]Tc-MY6349 successfully detected Trop2-positive tumors 15 min after tracer injection. Delayed imaging showed reduced uptake in normal organs but sustained retention of [99mTc]Tc-MY6349 in tumors. Importantly, [99mTc]Tc-MY6349 SPECT/CT imaging highlighted Trop2 expression heterogeneity and visualized primary and metastatic lesions with a favorable tumor-to-background ratio in breast cancer. Conclusion: [99mTc]Tc-MY6349 was successfully prepared and exhibited a high binding affinity and Trop2 specificity. The pilot clinical study validated the safety and feasibility of [99mTc]Tc-MY6349 SPECT/CT for detecting Trop2 expression in vivo in patients with breast cancer. This imaging modality could complement existing methods, aiding in the guidance of Trop2-targeted therapies and advancing personalized treatment while also promoting the application of SPECT/CT nuclear medicine imaging technology.
引用
- Sun Y, Hao Z, Gao H, et al. [99mTc]Tc-MY6349 Probe for Trop2-Targeted SPECT Imaging: From Preclinical to Pilot Clinical Study. J Nucl Med. 2025. PMID: 39947911. doi:10.2967/jnumed.124.268564
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。